Article Text
PDFReview
Essential thrombocythaemia and its neurological complications
Abstract
Essential thrombocythaemia is one of the chronic myeloproliferative neoplasms and is characterised by a sustained platelet count ≥450 × 109/l. The clinical course is often indolent but a significant number of patients have thrombotic and haemorrhagic complications. A patient with neurological complications is described, and the pathogenesis and clinical features of this disease are reviewed, including its neurological sequelae and management, along with an outline for the investigation of patients with thrombocytosis.
Statistics from Altmetric.com
Footnotes
Competing interests None.
Patient consent Obtained.
Provenance and peer review Commissioned; externally peer reviewed.
Read the full text or download the PDF:
Other content recommended for you
- Different immunophenotypical apoptotic profiles characterise megakaryocytes of essential thrombocythaemia and primary myelofibrosis
- Different expression patterns of LGALS1 and LGALS3 in polycythemia vera, essential thrombocythemia and primary myelofibrosis
- Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations
- Epigenomic profiling in polycythaemia vera and essential thrombocythaemia shows low levels of aberrant DNA methylation
- Gain-of-function gene mutations and venous thromboembolism: distinct roles in different clinical settings
- Vertebral artery thrombosis: a rare presentation of primary polycythaemia
- Sagittal sinus thrombosis in JAK2-V617F mutation without overt myeloproliferative disorder
- Essential thrombocythemia in a young man treated for myocardial infarction
- Off-pump coronary artery surgery in a patient with essential thrombocythaemia: two life-threatening complications in the same patient
- Molecular genetic tests for JAK2V617F, Exon12_JAK2 and MPLW515K/L are highly informative in the evaluation of patients suspected to have BCR-ABL1-negative myeloproliferative neoplasms